Stockreport

Disc Medicine After The CRL: Risk Now Rests On APOLLO [Seeking Alpha]

Disc Medicine, Inc.  (IRON) 
PDF The upcoming Phase 3 APOLLO trial, with improved endpoints and longer duration, is critical for linking PPIX reduction to real lifestyle improvement in EPP patients. [Read more]